Overview

* STAAR Surgical ( STAA ) Q3 preliminary net sales rise 6.9% yr/yr, beating analyst expectations

* Sales growth driven by recognition of deferred China shipment

* Lower new orders from China due to leaner inventory management

Outlook

* STAAR Surgical ( STAA ) did not provide specific future guidance in its press release

Result Drivers

* DEFERRED CHINA SHIPMENT - Recognition of $25.9 mln from December 2024 shipment boosted Q3 sales

* LOWER CHINA ORDERS - Lower new orders from China due to leaner inventory management

* INTERNATIONAL GROWTH - 7.7% growth in net sales outside China contributed to overall sales increase

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $94.70 $93.30

mln mln (7

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for STAAR Surgical Co ( STAA ) is $28.00, about 10.6% above its October 17 closing price of $25.03

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)